ALTSTATION.IO

Alexandria Real Estate Equities, Inc. (ARE) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$54.75

Change

-0.71%

Market Cap

$9.49B

Avg Volume

2.9M

Company Overview

Alexandria Real Estate Equities, Inc. (ARE) specializes in life science real estate. They own, operate, and develop properties designed for life sciences companies, primarily in major innovation hubs like Greater Boston, the San Francisco Bay Area, and New York City. Their clients are typically biotech and life science firms that require specialized spaces to conduct research and development, and Alexandria provides them with Class A/A+ office space and collaborative environments that foster innovation.

Alexandria is a market leader in the life science REIT sector, holding a considerable edge due to their focus on high-quality properties in prime locations. They face competition from other REITs and real estate companies targeting similar markets, like BioMed Realty and Healthpeak Properties. Market dynamics are favorable, with increased demand for life science facilities driven by rising biotech investments and a growing number of startups. However, economic headwinds, such as rising interest rates, could put pressure on real estate valuations and financing costs.

Currently, Alexandria is positioned for growth, bolstered by a favorable long-term outlook for life sciences. They recently expanded their footprint through new developments and strategic acquisitions, reinforcing their market presence. With a total market capitalization of $20.75 billion and significant ongoing construction projects, Alexandria is focused on leveraging its unique business model to enhance tenant relationships and ensure sustainable revenue streams. Their approach to providing strategic capital alongside real estate development could further strengthen their competitive advantage moving forward.

Key Financials

Market Cap

$9.49B

Revenue

$3.02B

EBITDA

$1.94B

Gross Margin

69.4%

Profit Margin

-47.4%

Revenue Growth

-5.2%

Total Cash

$549.06M

Total Debt

$12.76B

Free Cash Flow

$1.35B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

N/A

Forward P/E

-684.38

Beta

1.32

52-Week High

$105.14

52-Week Low

$44.10

EPS

$-8.44

50-Day Avg

$51.79

200-Day Avg

$68.47

Price/Book

0.60

Technical Analysis

Over the past 52 weeks, Alexandria Real Estate Equities, Inc. (ARE) has exhibited a strong downward trend, with a current price of $54.75 reflecting a significant decline of 37.7% from its peak near $100 in February. Key support levels are evident around $50, where the price has previously found buyers, while resistance is observed at approximately $55.9, which could act as a barrier to upward momentum. The chart shows a series of lower highs and lower lows, indicating a bearish price action and suggesting continued selling pressure. Recent momentum over the last few weeks shows a potential consolidation phase around the current price level, but it remains below the $55.9 resistance, limiting bullish prospects. At $54.75, the current price is situated near the lower end of the 52-week range, further indicating bearish sentiment and the potential for significant volatility if it breaks the support near $50.

Recent News and Developments

Here’s a summary of the latest news and developments for Alexandria Real Estate Equities, Inc

(ARE) stock in the past week:

1. Alexandria Real Estate Reports Significant Q4 2025 Net Loss Despite Revenue Beat

Alexandria Real Estate Equities, Inc. announced its fourth-quarter and full-year 2025 financial results, revealing a substantial net loss of $1.08 billion for Q4, primarily driven by a $1.72 billion real estate impairment charge. While the company’s revenue for the quarter surpassed analyst estimates, the significant impairment led to a full-year 2025 net loss of approximately $1.43 billion, impacting investor perceptions of its asset quality and balance sheet.

2. Goldman Sachs Initiates Coverage on ARE with “Neutral” Rating

On February 3, 2026, Goldman Sachs initiated coverage on Alexandria Real Estate Equities, Inc. (ARE) with a “Neutral” rating and set a price target of $60.00. This follows Citizens’ reiteration of a “Market Perform” rating on the stock on January 27, 2026, indicating a generally cautious but not negative sentiment from these investment banks.

Market Sentiment and Analyst Recommendations

Bull Case

ARE is trading at 52-week lows near $50 support after a brutal 37.7% decline, which creates a floor for aggressive value buyers. Goldman Sachs and Citizens both initiated neutral ratings rather than sell ratings, suggesting the worst-case scenario may be priced in. The $1.72 billion impairment charge is a one-time non-cash hit that clears the balance sheet of troubled assets, potentially stabilizing future earnings. Analyst consensus targets $60.14, implying 10% upside from current levels, with some bulls seeing 38% undervaluation. ARE operates in life sciences real estate, a sector with structural tailwinds from biotech funding and lab space demand that hasn’t disappeared despite macro weakness. The company still generated $3.02B in revenue despite the downturn, indicating core operations are functional.

Bear Case

The $1.08 billion Q4 net loss and $1.43 billion full-year loss signal serious portfolio problems that one impairment charge doesn’t fully resolve. Revenue contracted 5.2% year-over-year, showing tenant demand is weakening across the platform, not just in isolated assets. ARE carries $12.76 billion in debt against only $549 million in cash, leaving minimal flexibility if asset sales slow or refinancing costs spike. The stock has fallen 37.7% from $105 in February, and chart action shows lower highs and lower lows with resistance at $55.90, suggesting institutional selling pressure remains intact. The life sciences sector is cyclical, and biotech funding has cooled significantly in 2025-2026, directly threatening tenant quality and lease renewal rates. A break below the $50 support level could trigger capitulation selling given the technical damage already done.

What to Watch

Q1 2026 earnings will be critical to determine if the impairment was truly one-time or if further writedowns are coming. Track tenant retention rates and lease renewal spreads in the next quarterly report, since the 5.2% revenue decline suggests tenants are either leaving or renegotiating lower rates. Monitor ARE’s refinancing activity closely, particularly debt maturity schedules over the next 12-18 months, given the 23.2x debt-to-cash ratio leaves no room for error. Watch biotech funding indices and venture capital deployment trends, since life sciences real estate demand is directly correlated to biotech sector health. If ARE can stabilize revenue growth and hold the $50 support level through Q2, the stock could retest the $60 analyst target. Conversely, another 10% decline below $50 would suggest further institutional capitulation and potential distressed selling.

Analyst Consensus

HOLD

Based on 14 analyst opinions

Low Target

$50.00

Mean Target

$60.14

High Target

$70.00

Earnings and Financial Data

Sector

Real Estate

Industry

REIT – Office

Employees

514

Earnings & Dividends

Next Earnings

Jan 26, 2026

EPS (Trailing)

$-8.44

Dividend Yield

849.0%

Payout Ratio

689.5%

Frequently Asked Questions

Is ARE a good stock to buy?

Currently, analysts recommend a HOLD on Alexandria Real Estate Equities, Inc. (ARE) with a target price of $60.14. Given its current trading price of $54.75, there’s limited upside potential, so cautious investors might want to wait for more favorable conditions.

What is ARE’s price target?

The analyst price target for ARE is $60.14. This suggests a potential upside of about 9.5% from its current price, implying it may offer a modest return in the short term.

Does ARE pay a dividend?

Yes, ARE offers a remarkably high dividend yield of 849.0%. However, it’s important to scrutinize the sustainability of such a yield, especially in light of the company’s forward P/E of -684.38.

What is the range of ARE’s stock over the past year?

Alexandria’s stock has traded between $44.10 and $105.14 in the last 52 weeks. This volatility highlights the risk involved, especially for investors entering the stock near its highs.

Why is there no P/E ratio for ARE?

ARE currently has a P/E ratio of N/A due to its negative earnings. This typically indicates poor financial performance or losses, which investors should take into account before deciding to invest.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.